Esperion Therapeutics Inc...

NASDAQ: ESPR · Real-Time Price · USD
2.07
0.13 (6.70%)
At close: Aug 14, 2025, 3:59 PM
2.09
0.97%
Pre-market: Aug 15, 2025, 07:19 AM EDT

Esperion Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
332.31M 116.33M 75.47M 78.45M
Cost of Revenue
68.6M 43.27M 26.97M 14.22M
Gross Profit
263.71M 73.07M 48.51M 64.23M
Operating Income
54.4M -155.56M -179.5M -226.73M
Interest Income
n/a n/a n/a 112K
Pretax Income
-51.74M -209.25M -233.66M -269.11M
Net Income
-51.74M -209.25M -287.82M -318.82M
Selling & General & Admin
163.07M 142.52M 109.08M 184.99M
Research & Development
46.24M 86.11M 118.93M 105.97M
Other Expenses
n/a n/a n/a n/a
Operating Expenses
209.31M 228.63M 228.01M 290.96M
Interest Expense
59.25M 58.98M 56.81M 46.35M
Selling & Marketing Expenses
25.5M n/a 11.3M 13.7M
Cost & Expenses
277.91M 271.9M 254.98M 305.18M
Income Tax Expense
n/a n/a 54.16M 49.72M
Shares Outstanding (Basic)
187.18M 103.11M 66.41M 28.9M
Shares Outstanding (Diluted)
187.18M 103.11M 66.41M 28.9M
EPS (Basic)
-0.28 -2.03 -4.33 -11.03
EPS (Diluted)
-0.28 -2.03 -4.33 -11.03
EBITDA
7.57M -150.11M -176.35M -222.14M
EBIT
7.51M -150.27M -176.85M -222.75M
Depreciation & Amortization
63K 164K 500K 612K